 | • レポートコード：MRC2012B0637 • 出版社/出版日：GlobalInfoResearch / 2020年12月24日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、リーシュマニア症治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。リーシュマニア症治療の種類別市場規模（アンチモン酸メグルミン、ペンタミジン、ヒドロキシルアミジンスチルベン、アムホテリシンB）、用途別市場規模（内臓リーシュマニア症、皮膚リーシュマニア症）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Merck、AEterna Zentaris AG、iCo Therapeutics、Dafra Pharma、AEterna Zentaris、Pieris Pharmaceuticals、Eurofins Advinus ・地域別グローバル市場分析 2015年-2020年 ・リーシュマニア症治療の北米市場（アメリカ、カナダ、メキシコ） ・リーシュマニア症治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・リーシュマニア症治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・リーシュマニア症治療の南米市場（ブラジル、アルゼンチン） ・リーシュマニア症治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：アンチモン酸メグルミン、ペンタミジン、ヒドロキシルアミジンスチルベン、アムホテリシンB ・用途別分析：内臓リーシュマニア症、皮膚リーシュマニア症 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Leishmaniasis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The global Leishmaniasis Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.8%% in the forecast period of 2020 to 2025 and will expected to reach USD 115.4 million by 2025, from USD 96 million in 2019.
Market segmentation
Leishmaniasis Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Leishmaniasis Treatment market has been segmented into:
Meglumine Antimoniate
Pentamidine
Hydroxyl Amidine Stilbene
Amphotericin B
By Application, Leishmaniasis Treatment has been segmented into:
Visceral Leishmaniasis
Cutaneous Leishmaniasis
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Leishmaniasis Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Leishmaniasis Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Leishmaniasis Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Leishmaniasis Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Leishmaniasis Treatment Market Share Analysis
Leishmaniasis Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Leishmaniasis Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Leishmaniasis Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Leishmaniasis Treatment are:
Merck
AEterna Zentaris AG
iCo Therapeutics
Dafra Pharma
AEterna Zentaris
Pieris Pharmaceuticals
Eurofins Advinus
Among other players domestic and global, Leishmaniasis Treatment market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Leishmaniasis Treatment Market Overview
1.1 Product Overview and Scope of Leishmaniasis Treatment
1.2 Classification of Leishmaniasis Treatment by Type
1.2.1 Global Leishmaniasis Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Leishmaniasis Treatment Revenue Market Share by Type in 2019
1.2.3 Meglumine Antimoniate
1.2.4 Pentamidine
1.2.5 Hydroxyl Amidine Stilbene
1.2.6 Amphotericin B
1.3 Global Leishmaniasis Treatment Market by Application
1.3.1 Overview: Global Leishmaniasis Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Visceral Leishmaniasis
1.3.3 Cutaneous Leishmaniasis
1.4 Global Leishmaniasis Treatment Market by Regions
1.4.1 Global Leishmaniasis Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Leishmaniasis Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Leishmaniasis Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Leishmaniasis Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Leishmaniasis Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Leishmaniasis Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Leishmaniasis Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck SWOT Analysis
2.1.4 Merck Product and Services
2.1.5 Merck Leishmaniasis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 AEterna Zentaris AG
2.2.1 AEterna Zentaris AG Details
2.2.2 AEterna Zentaris AG Major Business
2.2.3 AEterna Zentaris AG SWOT Analysis
2.2.4 AEterna Zentaris AG Product and Services
2.2.5 AEterna Zentaris AG Leishmaniasis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 iCo Therapeutics
2.3.1 iCo Therapeutics Details
2.3.2 iCo Therapeutics Major Business
2.3.3 iCo Therapeutics SWOT Analysis
2.3.4 iCo Therapeutics Product and Services
2.3.5 iCo Therapeutics Leishmaniasis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Dafra Pharma
2.4.1 Dafra Pharma Details
2.4.2 Dafra Pharma Major Business
2.4.3 Dafra Pharma SWOT Analysis
2.4.4 Dafra Pharma Product and Services
2.4.5 Dafra Pharma Leishmaniasis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 AEterna Zentaris
2.5.1 AEterna Zentaris Details
2.5.2 AEterna Zentaris Major Business
2.5.3 AEterna Zentaris SWOT Analysis
2.5.4 AEterna Zentaris Product and Services
2.5.5 AEterna Zentaris Leishmaniasis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Pieris Pharmaceuticals
2.6.1 Pieris Pharmaceuticals Details
2.6.2 Pieris Pharmaceuticals Major Business
2.6.3 Pieris Pharmaceuticals Product and Services
2.6.4 Pieris Pharmaceuticals Leishmaniasis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Eurofins Advinus
2.7.1 Eurofins Advinus Details
2.7.2 Eurofins Advinus Major Business
2.7.3 Eurofins Advinus Product and Services
2.7.4 Eurofins Advinus Leishmaniasis Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Leishmaniasis Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Leishmaniasis Treatment Players Market Share
3.2.2 Top 10 Leishmaniasis Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Leishmaniasis Treatment Revenue and Market Share by Regions
4.2 North America Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
5 North America Leishmaniasis Treatment Revenue by Countries
5.1 North America Leishmaniasis Treatment Revenue by Countries (2015-2020)
5.2 USA Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
6 Europe Leishmaniasis Treatment Revenue by Countries
6.1 Europe Leishmaniasis Treatment Revenue by Countries (2015-2020)
6.2 Germany Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
6.4 France Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Leishmaniasis Treatment Revenue by Countries
7.1 Asia-Pacific Leishmaniasis Treatment Revenue by Countries (2015-2020)
7.2 China Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
7.5 India Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
8 South America Leishmaniasis Treatment Revenue by Countries
8.1 South America Leishmaniasis Treatment Revenue by Countries (2015-2020)
8.2 Brazil Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Leishmaniasis Treatment by Countries
9.1 Middle East & Africa Leishmaniasis Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Leishmaniasis Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Leishmaniasis Treatment Market Forecast by Type (2019-2024)
10.3 Meglumine Antimoniate Revenue Growth Rate (2015-2025)
10.4 Pentamidine Revenue Growth Rate (2015-2025)
10.5 Hydroxyl Amidine Stilbene Revenue Growth Rate (2015-2025)
10.6 Amphotericin B Revenue Growth Rate (2015-2025)
11 Global Leishmaniasis Treatment Market Segment by Application
11.1 Global Leishmaniasis Treatment Revenue Market Share by Application (2015-2020)
11.2 Leishmaniasis Treatment Market Forecast by Application (2019-2024)
11.3 Visceral Leishmaniasis Revenue Growth (2015-2020)
11.4 Cutaneous Leishmaniasis Revenue Growth (2015-2020)
12 Global Leishmaniasis Treatment Market Size Forecast (2021-2025)
12.1 Global Leishmaniasis Treatment Market Size Forecast (2021-2025)
12.2 Global Leishmaniasis Treatment Market Forecast by Regions (2021-2025)
12.3 North America Leishmaniasis Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Leishmaniasis Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Leishmaniasis Treatment Revenue Market Forecast (2021-2025)
12.6 South America Leishmaniasis Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Leishmaniasis Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Leishmaniasis Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Leishmaniasis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Leishmaniasis Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Leishmaniasis Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Leishmaniasis Treatment Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Merck Corporate Information, Location and Competitors
Table 7. Merck Leishmaniasis Treatment Major Business
Table 8. Merck Leishmaniasis Treatment Total Revenue (USD Million) (2017-2018)
Table 9. Merck SWOT Analysis
Table 10. Merck Leishmaniasis Treatment Product and Solutions
Table 11. Merck Leishmaniasis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. AEterna Zentaris AG Corporate Information, Location and Competitors
Table 13. AEterna Zentaris AG Leishmaniasis Treatment Major Business
Table 14. AEterna Zentaris AG Leishmaniasis Treatment Total Revenue (USD Million) (2018-2019)
Table 15. AEterna Zentaris AG SWOT Analysis
Table 16. AEterna Zentaris AG Leishmaniasis Treatment Product and Solutions
Table 17. AEterna Zentaris AG Leishmaniasis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. iCo Therapeutics Corporate Information, Location and Competitors
Table 19. iCo Therapeutics Leishmaniasis Treatment Major Business
Table 20. iCo Therapeutics Leishmaniasis Treatment Total Revenue (USD Million) (2017-2018)
Table 21. iCo Therapeutics SWOT Analysis
Table 22. iCo Therapeutics Leishmaniasis Treatment Product and Solutions
Table 23. iCo Therapeutics Leishmaniasis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Dafra Pharma Corporate Information, Location and Competitors
Table 25. Dafra Pharma Leishmaniasis Treatment Major Business
Table 26. Dafra Pharma Leishmaniasis Treatment Total Revenue (USD Million) (2017-2018)
Table 27. Dafra Pharma SWOT Analysis
Table 28. Dafra Pharma Leishmaniasis Treatment Product and Solutions
Table 29. Dafra Pharma Leishmaniasis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. AEterna Zentaris Corporate Information, Location and Competitors
Table 31. AEterna Zentaris Leishmaniasis Treatment Major Business
Table 32. AEterna Zentaris Leishmaniasis Treatment Total Revenue (USD Million) (2017-2018)
Table 33. AEterna Zentaris SWOT Analysis
Table 34. AEterna Zentaris Leishmaniasis Treatment Product and Solutions
Table 35. AEterna Zentaris Leishmaniasis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Pieris Pharmaceuticals Corporate Information, Location and Competitors
Table 37. Pieris Pharmaceuticals Leishmaniasis Treatment Major Business
Table 38. Pieris Pharmaceuticals Leishmaniasis Treatment Total Revenue (USD Million) (2017-2018)
Table 39. Pieris Pharmaceuticals SWOT Analysis
Table 40. Pieris Pharmaceuticals Leishmaniasis Treatment Product and Solutions
Table 41. Pieris Pharmaceuticals Leishmaniasis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Eurofins Advinus Corporate Information, Location and Competitors
Table 43. Eurofins Advinus Leishmaniasis Treatment Major Business
Table 44. Eurofins Advinus Leishmaniasis Treatment Total Revenue (USD Million) (2017-2018)
Table 45. Eurofins Advinus SWOT Analysis
Table 46. Eurofins Advinus Leishmaniasis Treatment Product and Solutions
Table 47. Eurofins Advinus Leishmaniasis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Global Leishmaniasis Treatment Revenue (Million USD) by Players (2015-2020)
Table 49. Global Leishmaniasis Treatment Revenue Share by Players (2015-2020)
Table 50. Global Leishmaniasis Treatment Revenue (Million USD) by Regions (2015-2020)
Table 51. Global Leishmaniasis Treatment Revenue Market Share by Regions (2015-2020)
Table 52. North America Leishmaniasis Treatment Revenue by Countries (2015-2020)
Table 53. North America Leishmaniasis Treatment Revenue Market Share by Countries (2015-2020)
Table 54. Europe Leishmaniasis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 55. Asia-Pacific Leishmaniasis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 56. South America Leishmaniasis Treatment Revenue by Countries (2015-2020)
Table 57. South America Leishmaniasis Treatment Revenue Market Share by Countries (2015-2020)
Table 58. Middle East and Africa Leishmaniasis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 59. Middle East and Africa Leishmaniasis Treatment Revenue Market Share by Countries (2015-2020)
Table 60. Global Leishmaniasis Treatment Revenue (Million USD) by Type (2015-2020)
Table 61. Global Leishmaniasis Treatment Revenue Share by Type (2015-2020)
Table 62. Global Leishmaniasis Treatment Revenue Forecast by Type (2021-2025)
Table 63. Global Leishmaniasis Treatment Revenue by Application (2015-2020)
Table 64. Global Leishmaniasis Treatment Revenue Share by Application (2015-2020)
Table 65. Global Leishmaniasis Treatment Revenue Forecast by Application (2021-2025)
Table 66. Global Leishmaniasis Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Leishmaniasis Treatment Picture
Figure 2. Global Leishmaniasis Treatment Revenue Market Share by Type in 2019
Figure 3. Meglumine Antimoniate Picture
Figure 4. Pentamidine Picture
Figure 5. Hydroxyl Amidine Stilbene Picture
Figure 6. Amphotericin B Picture
Figure 7. Leishmaniasis Treatment Revenue Market Share by Application in 2019
Figure 8. Visceral Leishmaniasis Picture
Figure 9. Cutaneous Leishmaniasis Picture
Figure 10. Global Leishmaniasis Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Leishmaniasis Treatment Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Leishmaniasis Treatment Revenue Market Share in 2019
Figure 19. Global Top 10 Players Leishmaniasis Treatment Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Leishmaniasis Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Leishmaniasis Treatment Revenue Market Share by Regions (2015-2020)
Figure 23. Global Leishmaniasis Treatment Revenue Market Share by Regions in 2018
Figure 24. North America Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 25. Europe Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 27. South America Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 29. North America Leishmaniasis Treatment Revenue Market Share by Countries (2015-2020)
Figure 30. North America Leishmaniasis Treatment Revenue Market Share by Countries in 2019
Figure 31. USA Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 32. Canada Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Europe Leishmaniasis Treatment Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Leishmaniasis Treatment Revenue Market Share by Countries in 2019
Figure 36. Germany Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 37. UK Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 38. France Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 39. Russia Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 40. Italy Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Leishmaniasis Treatment Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Leishmaniasis Treatment Revenue Market Share by Countries in 2019
Figure 43. China Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 44. Japan Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 45. Korea Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 46. India Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 48. South America Leishmaniasis Treatment Revenue Market Share by Countries (2015-2020)
Figure 49. South America Leishmaniasis Treatment Revenue Market Share by Countries in 2019
Figure 50. Brazil Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Leishmaniasis Treatment Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Leishmaniasis Treatment Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 55. UAE Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Leishmaniasis Treatment Revenue and Growth Rate (2015-2020)
Figure 58. Global Leishmaniasis Treatment Revenue Share by Type (2015-2020)
Figure 59. Global Leishmaniasis Treatment Revenue Share by Type in 2019
Figure 60. Global Leishmaniasis Treatment Market Share Forecast by Type (2021-2025)
Figure 61. Global Meglumine Antimoniate Revenue Growth Rate (2015-2020)
Figure 62. Global Pentamidine Revenue Growth Rate (2015-2020)
Figure 63. Global Hydroxyl Amidine Stilbene Revenue Growth Rate (2015-2020)
Figure 64. Global Amphotericin B Revenue Growth Rate (2015-2020)
Figure 65. Global Leishmaniasis Treatment Revenue Share by Application (2015-2020)
Figure 66. Global Leishmaniasis Treatment Revenue Share by Application in 2019
Figure 67. Global Leishmaniasis Treatment Market Share Forecast by Application (2021-2025)
Figure 68. Global Visceral Leishmaniasis Revenue Growth Rate (2015-2020)
Figure 69. Global Cutaneous Leishmaniasis Revenue Growth Rate (2015-2020)
Figure 70. Global Leishmaniasis Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Leishmaniasis Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Leishmaniasis Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Leishmaniasis Treatment Revenue Market Forecast (2021-2025)
Figure 74. Europe Leishmaniasis Treatment Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Leishmaniasis Treatment Revenue Market Forecast (2021-2025)
Figure 76. South America Leishmaniasis Treatment Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Leishmaniasis Treatment Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
リーシュマニア症治療の世界市場（～2026年） A drug used to treat diseases caused by parasitic protozoa leishmania Market Analysis and Insights: Global Leishmaniasis Treatment Market The global Leishmaniasis Treatment market size is projected to reach US$ 131.3 million by 2026, from US$ 98.1 million in 2020, at a CAGR of 5.0% during 2021-2026.…- 軟骨無形成症治療の世界市場（～2026年） Market Analysis and Insights: Global Achondroplasia Treatment Market The global Achondroplasia Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Achondroplasia Treatment Scope and Market Size Achondroplasia Tre…
- クラッベ病治療の世界市場（～2026年） Krabbe disease (KD) (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessi…
- 交流電場腫瘍治療の世界市場（～2026年） Alternating electric field tumor therapy is an anticancer treatment which disrupts the tumor cells mitosis. Alternating electric field therapy is a low intensity technique which disrupts the division of cells through physical interaction of molecules during mitosis in tumor cancer. The alternating e…
- 高カルシウム血症治療の世界市場（～2026年） Hypercalcemia is a condition caused by above normal levels of calcium in the body, with serum calcium level greater than 2.6 mmol/L. It is a life threatening metabolic disorder associated with neoplastic diseases and occurs in 10% to 20% of all adults suffering from cancer; particularly lung and bre…